Sir,

Detection of alloantibodies is one of the main objectives of compatibility work-up before transplantation. One of the common strategies employed in India is to perform complement-dependent cytotoxicity cross-match (CDC) and flow cytometry-based cross-match (FCXM) tests. If either or both of these tests are positive, Luminex-based single antigen bead (SAB) assay is performed to identify specific antibodies. These antibodies are then matched with human-leukocyte antigens (HLA) of prospective donor to determine donor-specific antibody (DSA), called virtual cross-match. Routinely matching is done at antigen level; not at epitope level. Antibodies positive at antigen level can be negative at epitope level and vice versa. Epitopes are configurations of polymorphic amino acid residues that are recognized by B cells, and antibodies reactive with these epitopes lead to rejection and/or premature allograft loss. We report our experience of two cases having history of sensitization, where class II (DPA1) antibody was ruled out as a DSA, only because of epitope analysis. Since this has a clinical implication of deciding the prospective kidney donor, epitope analysis may be used routinely in all SAB test interpretation.

Recipient serum samples were collected for Luminex SAB assay (LIFECODES LSA™ Kit Immucor Transplant Diagnostics, Inc. USA.) to identify the DSA. Luminex software (Match IT antibody) was used for antigen-based analysis (cut-off; BCM ≥1000/positive by machine) and Epitope-based analysis was done with the help of freely available online software ‘HLA Matchmaker’ (http://www.epitopes.net).

As described in Table 1, we presented two cases where both the patients and prospective donors were females, having history of sensitization. All three tests (CDCXM, FCXM, and SAB) were performed for pre-transplant workup. In the first case, CDC cross-match was negative and FCXM was positive for both T and B cells and in the second case CDC and B cell FCXM were negative; T cell FCXM was positive. DSA was identified in class I and class II in both cases. DSA allele matching at antigen and epitope level was performed. In both cases, epitope analysis revealed that antibody against DP locus was not DSA.

Both these patients had significant DSA in class I (case I - B*44:03 and case II - B*44:02) and class II (case I-DRB1*10:01; DPA1*02:01- DPB1*04:01 and case II DPA1*01:03-DPB1*06:01). Case 2 underwent desensitization by therapeutic plasma exchange (TPE) followed by retesting for median fluorescence intensity MFI. The patient (case 2) underwent successful renal transplant once MFI below 500 was achieved. However, what we would like the readers of journal know that if we had considered antigen-based analysis only and if these Class II (case I- DPA1*02:01- DPB1*04:01 and case II; DPA1*01:03-DPB1*06:01) were the only antibodies present in the recipient; it would have led to donor deferral. The epitope-based analysis resolved that DPA1*02:01- DPB1*04:01 in case I and DPA1*01:03-DPB1*06:01 in case II were not DSA and these patients could have undergone successful transplant even without TPE. India is a predominantly live-related transplant setting where only close relatives can be organ donors as per Transplantation of Human Organs and Tissues Act (THOTA) 2014. To have a willing donor in the family, by itself is difficult and any unnecessary deferral would be catastrophic for the recipient and her/his family. It is in this light, that epitope-based analysis assumes even greater significance.

Pre-transplant Compatibility Tests in Kidney Transplants: Case Report on Significance of Epitope-based Analysis in Donor Selection

© 2019 Indian Journal of Nephrology | Published by Wolters Kluwer - Medknow
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Chhavi Rajvanshi, Aseem Kumar Tiwari, Jui Choudhuri, Simmi Mehra, Rajni Chauhan
Department of Transfusion Medicine, Medanta-The Medicity, Sector-38, Gurugram, Haryana, India

Address for correspondence:
Ms. Chhavi Rajvanshi,
Department of Transfusion Medicine, Medanta-The Medicity, Sector-38,
Gurugram - 122 001, Haryana, India.
E-mail: chhavirajvanshi@gmail.com

References
1. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual cross-match. Hum Immunol 2009;70:574‑9.
2. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008;20:602‑6.
3. Duquesnoy RJ. Clinical usefulness of HLA Matchmaker in HLA epitope matching for organ transplantation. Curr Opinion Immunol 2008;20:594‑601.
4. René J. Duquesnoy. HLA epitope based matching for transplantation. Transpl Immunol 2014;31:1‑6.
5. Aggarwal G, Tiwari AK, Dorwal P, Chauhan R, Arora D, Dara RC, et al. Successful renal transplantation across HLA barrier: Report from India. Indian J Nephrol 2017;27:210.
6. Sahay M. Transplantation of human organs and tissues Act-“Simplified”. Indian J Transplant 2018;12:84‑9.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Table 1: HLA typing, pretransplant compatibility testing, and DSA on the basis of epitope matching.

| Case 1 | Recipient | Age/Sex | Sensitization | CDC | FCXM | DSA antigen matching | Epitope matching |
|--------|-----------|---------|---------------|-----|------|---------------------|-----------------|
|        | A         | B       | 02,11 13,18   | Yes | DR   | DB | DP | DRB1*07:01 | 162GLS |
|        | B         | DR      | 07,11        | ND  | DQA  | ND | ND | ND | ND |
|        | DR        | DQA     | 07,11        | ND  | DQB  | ND | ND | ND | ND |
|        | DRB1*07:01| DQB1*07:01| ND           | ND  | DPA  | ND | ND | ND | ND |
|        | DPB1*07:01| DPB1*07:01| ND           | ND  | DPA  | ND | ND | ND | ND |
|        | DRB1*07:01| DPA1*02:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |
|        | DPA1*02:01| DPB1*07:01| 1018         | 04:01 | DRB1*07:01 | 1018 | 04:01 | DRB1*07:01 | 1018 |

Table 2: Pretransplant compatibility testing and DSA on the basis of epitope matching.

| Age/Sex | Relationship | CDC | FCXM | DSA antigen matching | Epitope matching |
|---------|--------------|-----|------|---------------------|-----------------|
| 47/F    | Daughter     | Yes | DR   | DRB1*07:01          | 162GLS |
| 27/F    | Daughter     | Yes | DR   | DRB1*07:01          | 162GLS |
| 30/F    | Mother       | Yes | DR   | DRB1*07:01          | 162GLS |
| 54/F    | Mother       | Yes | DR   | DRB1*07:01          | 162GLS |

CDC: Complement-dependent cytotoxicity cross-match; FCXM: Flow cytometry-based cross-match; DSA: Donor-specific antibodies.

Quick Response Code: 10.4103/ijn.IJN_30_19

How to cite this article: Rajvanshi C, Tiwari AK, Choudhuri J, Mehra S, Chauhan R. Pre-transplant compatibility tests in kidney transplants: Case report on significance of epitope-based analysis in donor selection. Indian J Nephrol 2020;30:57-8.

Received: 19-01-2019. Revised: 20-04-2019. Accepted: 21-05-2019. Published: 06-09-2019
© 2019 Indian Journal of Nephrology | Published by Wolters Kluwer - Medknow